http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
-
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
-
Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Vallon Pharmaceuticals Inc. (VLON) Prices 3.7M Share Offering at $1.06/sh
-
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
-
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
-
Vallon Pharmaceuticals (VLON) Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
-
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
-
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
-
Vallon Pharmaceuticals (VLON) Issued Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
-
Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
-
Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
-
Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Vallon Pharmaceuticals Inc. (VLON) Announces Review of Strategic Alternatives
-
Vallon Pharmaceuticals Announces Review of Strategic Alternatives
-
Vallon Pharmaceuticals Announces Review of Strategic Alternatives
-
Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum
-
Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum
-
Vallon Pharmaceuticals Inc. (VLON) Study for Lead Program, ADAIR, for the Treatment of ADHD Did Not Meet its Primary Endpoint
-
Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
-
Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
-
Vallon Pharmaceuticals Inc. (VLON) Appoints Meenu Karson to its Board
-
Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
-
Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
-
Vallon Pharmaceuticals (VLON) Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
-
Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
-
Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
-
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
-
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
-
Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
-
Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
-
Vallon Pharmaceuticals Inc. (VLON) Reports New Data from Adult Stimulant Abuse Pattern Survey
-
Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference
-
Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference
-
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
-
Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
-
Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
-
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
-
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
-
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event
-
Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event
-
Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
-
Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
-
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
-
Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting
-
Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting

